---
document_datetime: 2023-09-21 18:41:35
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/riprazo-hct-epar-public-assessment-report_en.pdf
document_name: riprazo-hct-epar-public-assessment-report_en.pdf
version: success
processing_time: 1.7438712
conversion_datetime: 2025-12-31 04:26:08.05188
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 January 2011 EMA/745107/2011 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Riprazo HCT

aliskiren hemifumarate / hydrochlorothiazide

Procedure No.:

## Note

<!-- image -->

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

EMEA/H/C/002420/0000 Medicinal product no longer authorised

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0)20 7523 7455

E-mail info@ema.europa.eu Website www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

1. Background information on the procedure .............................................. 3

1.1. Submission of the dossier.................................................................................... 3

Information on Paediatric requirements ....................................................................... 3

Scientific Advice ....................................................................................................... 3

Licensing status ....................................................................................................... 3

1.2. Steps taken for the assessment of the product ....................................................... 4

2. Scientific discussion ................................................................................ 4

2.1. Introduction ...................................................................................................... 4

2.2. Quality aspects .................................................................................................. 4

2.3. Non-clinical aspects............................................................................................ 5

2.4. Clinical aspects .................................................................................................. 5

2.5. Pharmacovigilance.............................................................................................. 5

2.6. Benefit-Risk assessment ..................................................................................... 6

2.7. Recommendation ............................................................................................... 6

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Novartis Europharm Ltd. submitted on 5 November 2010 an application for Marketing Authorisation  to  the  European  Medicines  Agency  (EMA)  for  Riprazo  HCT,  through  the  centralised procedure under Article  3  (2)  (a)  of  Regulation  (EC)  No  726/2004.  The  eligibility  to  the  centralised procedure was agreed upon by the EMA/CHMP on 23 September 2010.

The  legal  basis  for  this  application  refers  to Article  10(c)  of  Directive  2001/83/EC,  as  amended  relating  to  informed  consent  from  a  marketing  authorisation  holder  Novartis  Europharm  Ltd.  for  an authorised medicinal product Rasilez HCT (EU/1/08/491/001-080).

The application submitted is composed of administrative information, quality, non-clinical and clinical data with a letter from a MAH Novartis Europharm Ltd. allowing the cross reference to relevant quality, non-clinical and/or clinical data.

The applicant applied for the following indication:

'Treatment of essential hypertension in adults.

Riprazo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Riprazo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.'

## Information on Paediatric requirements

Pursuant  to  Article  7  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/31/2009 for the following condition:

-  Essential hypertension.

on the granting of a (product-specific) waiver for

-  Essential hypertension.

## Scientific Advice

The applicant did not seek scientific advice at the CHMP.

## Licensing status

Medicinal product no longer authorised

The initial product Rasilez HCT was approved in the EU on 16 January 2009.

The  Rapporteur  and  Co-Rapporteur  appointed  by  the  CHMP  and  the  Rapporteur's  evaluation  team were:

Rapporteur:

Daniela Melchiorri

Co-Rapporteur:

János Borvendég

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

-  The application was received by the EMA on 5 November 2010.
-  The procedure started on 21 November 2010.
-  The Rapporteur's first Assessment Report was circulated to all CHMP members on 25 December 2010 (Annex 4.1).
-  During the meeting on 17-20 January 2011, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Riprazo HCT on 20 January 2011. The applicant provided the letter of undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  18  January  2011 (Annex 4.2).

## 2. Scientific discussion

## 2.1. Introduction

This  marketing  authorisation  application  for  Riprazo  HCT  (aliskiren/hydrochlorothiazide)  has  been submitted by Novartis Europharm Ltd as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended.

The MAH (Novartis Europharm Ltd) for Rasilez HCT, which was authorised on 16 January 2009 and submitted as a fixed combination application under Article 10(b) of Directive 2001/83/EC as amended, provided  consent  to  make  use  of  the  pharmaceutical,  non-clinical  and  clinical  documentation  of  the initial  dossier  of  this  authorised  product  and  any  subsequent  post-marketing  procedures  submitted, assessed and approved.

As a consequence, quality, safety and efficacy of the Riprazo HCT medicinal product are identical to the up-to-date  quality,  non-clinical  and  clinical  profile  of  Rasilez  HCT.  The  application  for  Riprazo  HCT concerns the identical strengths and pack sizes to those approved for Rasilez HCT and consists of only Module 1. Information on the scientific discussion can be found in the Rasilez HCT CHMP assessment reports and in the European Public Assessment Report (EPAR) published on the EMA website.

The approved indications are:

'Treatment of essential hypertension in adults.

Riprazo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Medicinal product no longer authorised

Riprazo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.'

## 2.2. Quality aspects

Since this application is an informed consent of the Rasilez HCT application, the quality data in support of the Riprazo HCT application are identical to the up-to-date quality data of the Rasilez HCT dossier, which have been assessed and approved (including all post-marketing procedures).

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

Since this application is an informed consent of the Rasilez HCT application, the non-clinical data in support of the Riprazo HCT application are identical to the up-to-date non-clinical data of the Rasilez HCT dossier, which have been assessed and approved (including all post-marketing procedures).

An environmental Risk Assessment has been provided, which is identical to the version submitted as a follow-up measure for Rasilez HCT.

## 2.4. Clinical aspects

Since this application is an informed consent of the Rasilez HCT application, the clinical data in support of the Riprazo HCT application are identical to the up-to-date clinical data of the Rasilez HCT dossier, which have been assessed and approved (including all post-marketing procedures).

The Applicant has made appropriate commitments to update the product information for Riprazo HCT post-authorisation in accordance with the outcome of ongoing regulatory procedures for Rasilez HCT. User consultation A justification  for  not  performing  a  full  user  consultation  with  target  patient  groups  on  the  package leaflet has been submitted by the applicant and has been found acceptable for the following reasons: In  view  of  the  fact  that  a  readability  test  had  been  performed  at  the  time  of  the  original  MAA  for Rasilez HCT and the content of the package leaflet is identical to the latest approved leaflet of Rasilez HCT, no further testing is warranted. 2.5. Pharmacovigilance PSURs As  requested  by  the  Applicant  and  agreed  by  the  CHMP,  the  PSUR  cycle  of  this  informed  consent application will be aligned with the PSUR cycle for the reference product, Rasilez HCT, unless otherwise specified. Detailed description of the pharmacovigilance system (DDPS) The  CHMP  considered  that  the  Pharmacovigilance  system  as  described  by  the  applicant  fulfils  the legislative requirements. Risk Management Plan Medicinal product no longer authorised

The Applicant submitted a risk management plan (version 6) identical with that for Rasilez HCT. The Applicant has made a post-authorisation commitment to provide an updated RMP version based on the outcome of the ongoing assessments of the latest RMP for Rasilez HCT.

The CHMP, having considered the data submitted in the application, is of the opinion that no additional risk minimisation activities are required beyond those included in the product information.

<div style=\"page-break-after: always\"></div>

## 2.6. Benefit-Risk assessment

This  marketing  authorisation  application  for  Riprazo  HCT  (aliskiren/hydrochlorothiazide)  has  been submitted by Novartis Europharm Ltd as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended.

The MAH (Novartis Europharm Ltd) for Rasilez HCT, which was authorised on 16 January 2009 and submitted as a fixed combination application under Article 10(b) of Directive 2001/83/EC as amended, provided  consent  to  make  use  of  the  pharmaceutical,  non-clinical  and  clinical  documentation  of  the initial  dossier  of  this  authorised  product  and  any  subsequent  post-marketing  procedures  submitted, assessed and approved.

As a consequence, quality, safety and efficacy of the Riprazo HCT medicinal product are identical to the up-to-date  quality,  non-clinical  and  clinical  profile  of  Rasilez  HCT.  The  application  for  Riprazo  HCT concerns the identical strengths and pack sizes to those approved for Rasilez HCT and consists of only Module 1. Information on the scientific discussion can be found in the Rasilez HCT CHMP assessment reports and in the European Public Assessment Report (EPAR) published on the EMA website.

Based on the assessment of all available data,  the CHMP concluded that the benefit/risk  balance is positive for the following proposed indications:

## 'Treatment of essential hypertension in adults.

Riprazo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Riprazo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.'

## 2.7. Recommendation

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considered by consensus that the benefit/risk balance of Riprazo HCT in the treatment of essential hypertension was favourable and therefore recommended the granting of the marketing authorisation.

Medicinal product no longer authorised